CNS Disorders  >>  crenezumab (RG7412)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
crenezumab (RG7412) / AC Immune
CREAD, NCT02670083 / 2015-003034-27: A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).

Not Appicable Jan 2020 - Dec 2020 : From CREAD1 trial in prodromal to mild Alzheimer's disease (trial terminated)
Terminated
3
813
Europe, Canada, Japan, US, RoW
Crenezumab, Placebo
Hoffmann-La Roche
Alzheimer's Disease
05/19
05/19
CREAD OLE, NCT03491150 / 2017-002702-12: An Open-Label Crenezumab Study in Participants With Alzheimer's Disease

Terminated
3
149
Europe, Canada, US, RoW
Crenezumab, RO5490245
Hoffmann-La Roche
Alzheimer's Disease
05/19
05/19
CREAD 2, NCT03114657 / 2016-003288-20: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

Hourglass Jan 2021 - Dec 2021 : From CREAD2 trial for prodromal to mild Alzheimer's disease
Terminated
3
806
Europe, Canada, Japan, US, RoW
Crenezumab, Placebo
Hoffmann-La Roche
Alzheimer's Disease
06/19
06/19

Download Options